Document resource
Background Achieving disease control (DC) and stability (DS) in COPD could be valuable goals to evaluate treatment effectiveness in real-world settings. Composite endpoints may be useful tools to assess DC and DS and provide a more holistic assessment by combining multiple measures including lung function, symptoms, and exacerbations.Methods This pooled analysis combined 4541-individual patient level data from six European, prospective, observational studies to assess the proportion of patients with COPD who met DC and DS outcomes following treatment with extra fine fixed dose combination of beclomethasone dipropionate, formoterol, and glycopyrronium (BDP/FF/G) in single inhaler. DC is defined as an improvement in Forced Expiratory Volume in the first second (FEV1) of ≥100 mL from baseline, a reduction of ≥2 points in the COPD Assessment Test (CAT) score, and 0 exacerbation. DS is stated as FEV1 increase or no change, CAT reduction or no change, and 0 exacerbations. DC and DS were analysed at 3 and 6 months of treatment with extra fine BDP/FF/G.Results The full analysis set included 4541 patients (62.3% male), with mean (SD) CAT score 21.5 (7.5), mean (SD) FEV1 1.38L (0.59), and mean (SD) exacerbation rate 1.6 (1.0). At 3 months (n=1694), 23.3% and 45.2% of patients achieved DC and DS, respectively. At 6 months (n=1554), 24.7% and 42.2% achieved DC and DS, respectively.Conclusions Treatment with extra fine single inhaler triple therapy BDP/FF/G represents an effective option to achieve disease control and stability in COPD patients in real-world setting, providing practical and patient-centric treatment goals.